ABSTRACT: Delayed healing and/or non-union occur in approximately 5-10% of the fractures that occur annually in the United States. Segmental bone loss increases the probability of non-union. Though grafting can be an effective treatment for segmental bone loss, autografting is limited for large defects since a limited amount of bone is available for harvest. Parathyroid hormone (PTH) is a key regulator of calcium homeostasis in the body and plays an important role in bone metabolism. Presently PTH is FDA approved for use as an anabolic treatment for osteoporosis. The anabolic effect PTH has on bone has led to research on its use for bone regeneration applications. Numerous studies in animal models have indicated enhanced fracture healing as a result of once daily injections of PTH. Similarly, in a human case study, non-union persisted despite treatment attempts with internal fixation, external fixation, and autograft in combination with BMP-7, until off label use of PTH1-84 was utilized. Use of a biomaterial scaffold to locally deliver PTH to a defect site has also been shown to improve bone formation and healing around dental implants in dogs and drill defects in sheep. Thus, PTH may be used to promote bone regeneration and provide an alternative to autograft and BMP for the treatment of large segmental defects and non-unions. This review briefly summarizes the unmet clinical need for improved bone regeneration techniques and how PTH may help fill that void by both systemically and locally delivered PTH for bone regeneration applications. ß
Bone generally has effective capacity to heal and, due to continuous remodeling of bone throughout adult life, healing often occurs with no scar. 1 However, delayed healing and/or non-union occur in an estimated 5-10% of the approximately 7.9 million fractures that occur annually in the United States. 2, 3 If the bone fracture healing process exceeds 3 months, healing is considered to be delayed. If healing is not achieved by 9 months with no evidence of new healing in the previous 3 months, the fracture is considered to be a non-union. Non-union incidence varies (ranging from 1.9% to 30%) depending on fracture location, configuration, and associated soft tissue damage, as well as other treatment and lifestyle factors. 4, 5 Factors that may disrupt healing and put patients at higher risk for non-union include, but are not limited to, inadequate immobilization, obesity, smoking, age, malnutrition, and multiple injury. [6] [7] [8] [9] [10] Segmental bone loss, infection, and complications from previous surgeries may also contribute to non-union. Open fractures, like those potentially caused by high energy trauma, or large bone defects caused by trauma or tumor resection have a higher relative risk for nonunion. [11] [12] [13] [14] Indirect costs, like productivity losses due to the injury, account for more than half of the total cost of long bone non-union. 15 Average cost for treatment of a long bone non-union was reported as US $11,333. 16 Current treatment options are dependent on location and type of non-union. For those complicated by segmental bone loss options include, but are not limited to; bone grafting, distraction osteogenesis, and bone transport, Masquelete technique, low intensity pulsed ultrasound (LIPUS) and pulsed electromagnetic field therapy (PEMF). Open fractures, non-unions complicated by segmental defects, or cases where removal of tissue at a site of non-union is necessary for treatment, 17 are typically addressed by shortening the bone or filling the defect. 18 Shortening the bone has a limit of 3 cm in the upper limb and 1 cm in the lower limb before inducing a functional deficit for that limb. Filling the gap is traditionally achieved via bone graft or bone transport. 18 The gold standard for bone grafting is autograft. Autograft has the major downfalls of donor site pain and morbidity as well as limited availability, [19] [20] [21] as it is impractical to harvest a sufficient amount of bone for repairing a critical size defect. As a result, allografts are a common alternative. However, allografts have a higher rate of failure (delayed or non-union, infection, or fracture) compared to autograft as well as potential for immunogenicity problems. 18, [22] [23] [24] [25] Regardless of the downfalls, grafting is presently the most effective option and approximately 2.2 million orthopaedic procedures utilize autograft or allograft each year to treat large orthopaedic defects. 26 The limitations of grafting, and other currently FDA approved methods, have led to progress in the exploration of bioactive molecules for promotion of bone regeneration. The cellular mechanisms behind bone regeneration are not completely understood, presenting challenges in optimizing alternatives to bone grafts. However, the components that are understood can be expanded upon as potential treatments. For example, stem cells, gene therapy, and growth and differentiation factors may all have potential for complex healing applications. Thus far, bone morphogenetic proteins (BMPs) have shown the most promise.
BMPs plays a role in bone regeneration and are known to robustly promote osteogenic differentiation. BMPs have, therefore, been combined with materials like hydroxyapatite, Di-calcium phosphate dehydrate (DCPD), collagen, PLGA, and poly(propylene fumarate) (PPF), many others in order to create an implant to promote bone healing. [27] [28] [29] [30] In 2001 the FDA approved OP-1 TM , a BMP-7 implant, as a potential alternative to autograft in recalcitrant long bone nonunion situations. A short time later, Infuse TM , bovine collagen with BMP-2, was FDA approved. Since then BMP-2 has become a prominent treatment option for spinal fusion applications, tibial fractures, and sinus repair. BMP-2 and BMP-7 have been shown to perform as well as iliac crest bone grafts (ICBG) for spinal fusion applications as well as long bone nonunion applications. BMP has also been effectively used to enhance chances of union after failed grafting in both tibial and femur non-unions, 31, 32 and in upper limb-non unions when used in conjunction with autologous bone graft. 33 BMP use may also be efficacious for some trauma applications. [34] [35] [36] [37] However, BMP use comes with the possibility of an increased risk of cancer at 24 months. 38 When BMP is used in nonspinal orthopaedic procedures, serious adverse events may lead to additional surgeries. 39 Like ICBG, the success of BMP is somewhat dependent on the type of fracture as well as other patient predispositions to non-union and is similarly, if not more, financially burdensome than ICBG. 40, 41 Thus, there is a need for additional alternative biologics to promote bone regeneration when complications arise.
Parathyroid hormone (PTH) is a molecule that has good potential for enhancing bone regeneration in large bone defects. This potential lies in the anabolic effect PTH has on bone. Daily injections of PTH are an effective FDA approved treatment for osteoporosis that results in increases in both bone mineral density and bone volume. Thus, PTH may promote bone regeneration and provide an alternative to autograft and BMP use for the treatment of large segmental defects and non-unions. In a case study, treatment attempts with internal fixation, external fixation, and autograft in combination with BMP-7, non-union persisted until off label use of PTH1-84 was utilized. 3 This review briefly summarizes how PTH may help fill the clinical need for improved bone regeneration techniques.
BIOLOGICAL MECHANISMS OF PTH MEDIATED BONE FORMATION
Parathyroid hormone, an 84 amino acid protein, is a key regulator of calcium homeostasis in the body. Normal secretion (from the parathyroid gland) is an ultradian rhythm with tonic and pulsatile components (70% tonic, 30% pulsatile), and is dependent on serum calcium and phosphorous. The half-life of PTH in humans is approximately 2-5 min and the pulsatile component is in low amplitude high frequency bursts every 10-20 min superimposed on the tonic secretion. 42, 43 The pulsatile component is highly sensitive to changes in ionized calcium and calcitrol levels. When extracellular calcium concentrations are outside of the normal range the parathyroid glands change secretion of PTH to return serum calcium levels to normal (using the skeleton as a calcium reservoir). The classic actions of PTH, including stimulating bone resorption and increasing calcium reabsorption, reside in the N-terminal 1-34 region of the protein. 44 PTH acts through a g-protein coupled receptor, type 1 PTH receptor (PTHR1). When PTH binds to the receptor, adenylate cyclase, or phospholipase C is activated starting a cascade that activates protein kinase A (PKA) or protein kinase C (PKC), respectively. 45 Activation of the PKA pathway is mediated by the Ga s part of the receptor, this cascade stimulates cAMP production, and subsequently PKA. Activation of the PKC pathway is a Ga q mediated response. PKC is activated through phospholipase C dependent and independent pathways, which leads to activation of osteoblastic bone formation. 46 Through these pathways PTH can mediate both bone formation and bone resorption. Thus, these pathways are generally credited with control of the classic actions of PTH. 47 However, the evidence suggesting PTH induces MSC differentiation to the osteoblast lineage is not necessarily explained through the traditional pathway. Anabolic effects may also stem from the effect PTH has on local factors like BMPs, Wnts, or TGFb through recruitment of their receptors to PTHR1 and/or endocytosis. 46, 48, 49 PTH has been shown to induce MSC differentiation to the osteoblast lineage through a signaling cascade that enhances BMP signaling. 50 Similarly, T lymphocytes express functional PTHR1 and PTH has been shown to increase the production of Wnt10b by bone marrow CD8þ T cells and induce lymphocytes to activate canonical Wnt signaling in preosteoblasts. 51, 52 Further supporting the role of T cells role in increasing capacity of stromal cells to support PTH induced effects, continuous infusion of PTH (mimicking hyperparathyroidism) fails to induce bone resorption and cortical bone loss in mice lacking T cells. 53 However, as the receptor for PTH is not found in osteoclasts osteoclast response to PTH is mediated through osteoblasts. 54, 55 The overall response of osteoblasts to PTH stimulation, however, is dependent on concentration and timing. Both tonic and pulsatile secretions play a role in normal bone maintenance, though it is not fully clear what role each plays. In glucocorticoid induced osteoporosis endogenous tonic PTH levels are decreased, and the amount released in pulsatile fashion is increased. 42 It has been proposed that the increase in pulsatile release is perhaps an attempt at compensation for the decrease in tonic release, however an osteoporotic state still develops. This raises the possibility of an underappreciated role of tonic (continuous) PTH secretions in normal bone maintenance that could be used to develop novel bone regeneration strategies.
Generally, continuously elevated serum PTH levels have catabolic effects in bone and intermittently elevated PTH is anabolic. This effect is observed in both animal and human models. Treatment of rats with continuous infusion of PTH 1-84 resulted in an increase in bone formation comparable to that associated with intermittent injection, but a more marked calcemic effect and thus a net decrease in trabecular bone. 56 Similarly, continuously administered PTH 1-34 caused a dose dependent decrease in dry weight of the femur and a hyperparathyroidism-like condition in the highest administered dose (214 ng/kg/h) in rats. 57 This effect is also observed at the cellular level. Continuous PTH 1-84 treatment for 7 days in mice resulted in an increase in osteoclast number at day 2 followed by an increase in osteoblast number at day 4. Whereas daily injections of PTH 1-84 did not affect osteoclast number and the increase in osteoblast number was significantly larger than that of continuous treatment. 58 Interestingly, in male Sprague Dawley rats continuous infusion of PTH 1-34 for 12 days (4 mg/100 g/day) had an inconsistent effect. Upon repeating the experiment three times, one of the three experiments showed bone formation was increased with continuous PTH treatment (n ¼ 7 per group) over that of vehicle treated animals. However, the other two experiments showed no difference between animals receiving vehicle treatment versus continuous PTH 1-34 treatment. 59 This variable response is somewhat consistent with what is observed in humans with primary hyperparathyroidism (PHPT). Cortical bone loss is characteristic of primary hyperparathyroidism, however trabecular bone may be preserved or even enhanced. 60, 61 In the classic presentation of PHPT, transiliac biopsies exhibit increased cortical porosity as well as reduced cortical width, but preservation, or enhancement, of trabecular bone architecture. 61 These findings have been corroborated by studies in, postmenopausal women with mild primary hyperparathyroidism (PTH levels: 116 þ/À 19 pg/ml, normal: 10-65 pg/ml). Post-menopausal women with mild PHPT showed preservation of trabecular bone whereas postmenopausal women without PHPT exhibited trabecular bone loss. 62, 63 Similarly, a study in patients with asymptomatic PHPT indicated bone mineral density was reduced at cortical sites, but at more cancellous sites (like the lumbar spine) it was preserved. 64 Other studies showed no correlation between mild asymptomatic PHPT and risk factor for vertebral fractures. 65 However, more recent studies indicated even if bone mineral density was preserved, the risk of vertebral fracture was higher in postmenopausal patients with mild PHPT. The risk of vertebral fracture appears independent of severity of PHPT. These observations on PHPT indicate there is some inconsistency in response to continuously elevated PTH. The reason for this is unclear. Studies have examined the correlation of demographic factors as well as co-existing deficiencies (like serum 25-hydroxyvitamin D (25OHD)) with severity of PHPT as well as the impact on BMD and bone turnover. [66] [67] [68] [69] [70] However, no clear explanation stands out. Perhaps there is a threshold above which continuously elevated PTH is catabolic and below which it is anabolic. As the preservative effects seem limited to sites of higher remodeling (like trabecular bone), continuously elevated PTH may also play a role in bone regeneration. Thus, it is possible that local delivery of PTH to a bone defect may promote bone healing while minimizing potential negative systemic effects.
Contrary to continuously elevated PTH, when intermittently administered, both PTH ). Intermittently administered PTH decreases the risk of fragility fractures, increases cortical thickness and improves trabecular bone architecture in the ilium of postmenopausal women, 74, 77 and increases bone mineral density (BMD) in the lumbar spine in both men and women. 78 In osteoporotic women, bone mineral density of the lumbar spine increases 6.3% with PTH treatment compared to an increase of 4.6% with alendronate (an anti-resorptive) treatment. 79 Similarly, a 14% increase in bone volume was observed in women with osteoporosis that received daily injections of PTH 1-34 compared to the 24% loss in bone volume in women with osteoporosis who were not treated with PTH. 77 These changes occur due to an unbalance in remodeling, favoring formation, caused by intermittent PTH (daily subcutaneous injection) therapy. 46, 80 It is important to note PTH treatment in humans is limited to 2 years and is associated with a "black box" warning for potential tumorigenic effects. Surveillance of human osteosarcoma patients has not yet detected a causal association between PTH therapy and osteosarcoma. 81 However, studies in F344 rats indicated a significant percentage of subjects developed osteosarcoma following two years of PTH 1-34 treatment. 82 Interestingly, in F344 rats, PTH 1-84 has an osteosarcoma incidence curve shifted to the right of PTH 1-34 indicating a lower incidence of osteosarcoma in rats given PTH 1-84 than 1-34. 83 Low dose (5-10 mg/kg) PTH resulted in no neoplastic changes, however high dose (>30 mg/kg) administered for 20-24 months (70-80% of lifespan) resulted in significant increases in osteosarcoma incidence. 83, 84 Similar studies in cynomolgus macaques indicated PTH 1-34 treatment (5 mg/ kg/d) for 18 months did not result in neoplastic changes over the course of the 18 months of treatment or the 3-year follow-up observation. 85 Though there is the potential tumorigenic effect with long-term high doses of PTH, the ability of PTH to increase bone formation makes it a molecule of interest for shortterm low dose bone regeneration applications.
EFFICACY OF SYSTEMIC PTH FOR BONE REGENERATION AND DEFECT REPAIR
Based on the success of PTH as an anabolic osteoporosis treatment, it follows that there may also be implications for its use for promoting bone regeneration in large bone defects. Though it may seem the benefits of utilizing PTH for bone regeneration are limited to intermittent administration, some of the aforementioned findings suggest continuously elevated PTH may be anabolic in certain circumstances, such as in mild PHPT 64 and tonic PTH secretions. 42, 43 The ability of PTH to increase remodeling in bone gives it great potential in the realm of fracture healing. 86 Incorporation of PTH into a treatment process for segmental defects could enhance healing. Research thus far has examined the potential of systemically administered PTH and PTH delivered locally (directly to the defect site).
Daily injections of PTH seem to have a consistently beneficial impact on healing of fractures, graft incorporation, implant fixation, distraction osteogenesis, and spinal fusion in animal models. [87] [88] [89] [90] [91] Treatment of rats with PTH 1-34 (60 mg/kg/day) resulted in a dense network of trabeculae in bone chambers as compared to control. 86 Similarly, treatment with PTH 35 mg/kg/ day or 105 mg/kg 3Â per week resulted in a dose dependent increase in bone ingrowth into bone chambers in rat calvaria. 89 Studies in mice examining treatment with 10, 40, and 200 mg/kg/day show similar dose dependent increases in bone formation in the fracture callus. 92 In male rats, 75 mg/kg/day PTH 1-84 for 12 weeks increased the healing of a femoral defect. 90 Daily injections of PTH 1-34 (15 nmol/kg/day) and PTH 1-31 (15 nmol/kg/day) have been shown to increase the external volume and strength of closed fracture calluses. 91 Similarly, closed fractures in rats treated with daily injections of PTH showed an increase in bone mineral content, bone mineral density, and cartilage volume. 93 Accelerated healing was observed with PTH treatment in a closed fracture model in female cynomolgus monkeys. 94 Systemic intermittent injections of PTH have a consistently anabolic effect on healing of closed fractures, indicating similar effects may be observed in more complex healing scenarios like open fractures or segmental bone defects.
An increase in union rate has not been observed as a result of PTH treatment for open fractures in animal models. However, like with closed fractures, treatment did increase callus volume, bone mineral content, and bone volume fraction. 95 Intermittent injections of PTH 1-34 have also been shown to enhance guided bone healing in rat calvarial defects. 96 And more recently, treatment with 100 mg/kg 3Â per week for 8 weeks increased union rate and accelerated healing in a refractory fracture model in rats. 97 Subcutaneous injections of 40 mg/kg/day PTH in mice resulted in enhanced healing (increased bone volume and BMC) in an open defect reconstructed with a PLA/bTCP scaffold. 98 Likewise, rats treated with injections of PTH 1-34 every other day during distraction osteogenesis showed increased callus volume and mechanical strength. 99 Bone graft healing in spinal fusion models is also enhanced by intermittently administered PTH 1-34. [100] [101] [102] Daily systemic injections of PTH 1-34 (40 mg/kg) enhance osseointegration of devitalized femoral allografts in a critical size femoral defect model in mice. 103 Daily injections of PTH 1-34 (5 mg/kg/day) also enhanced allograft incorporation in adult female mongrel hounds. 104 Though it is clear that PTH has positive impacts on bone regeneration, the ideal administration regime is yet to be determined. When the duration of PTH treatment (as daily injections) was investigated in mice, it was found that immediate treatment for only 2 weeks was sufficient to increase the ultimate torque of femurs with diaphyseal allografts, but 4 weeks of treatment showed no increased benefit in terms of bone strength. 105 Delaying the initiation of PTH treatment until 4 weeks after surgery was completely ineffective, whereas delaying only 1 or 2 weeks resulted in equivalent biomechanical properties as immediate treatment. 105 When PTH was administered at 15 mg/kg daily, 35 mg/kg 3 days/week, or 105 mg/kg once per week, all PTH treatments resulted in more bone formation than controls; however, PTH 105 mg/kg once per week resulted in greater bone formation than the other PTH groups. 106 Four weeks of PTH treatment in mice examining differences in low dose/high frequency (3 mg/kg, 3 times/day), low dose/low frequency (9 mg/kg, once/day), high dose/high frequency (9 mg/kg, 3 times/day), and high dose/low frequency (27 mg/kg, once/day) indicated high dose and/or high frequency treatment increased callus bone volume but did not have a significant impact on biomechanical recovery whereas low dose/low-frequency therapy resulted in a lesser increase in callus bone volume but significant increases in biomechanical recovery measures. 107 Likewise, studies by Sheyn et al. 108 indicate 0.4 mg/kg was more successful in accelerating and maintaining repair of bone defects in ostoportic rats than higher doses. Current FDA approved treatment is 20 mg/day (0.3-0.5 mg/kg) for up to 2 years when used in humans for treatment of osteoporosis. The dosages used in animal studies range from 0.4 to 40 mg/kg. Some studies show a dose response to PTH and some do not, however it should be acknowledging the higher doses in rodent studies are necessarily less clinically relevant. Still, the high dose may be utilized for studies ranging from 4 to 12 weeks in duration as opposed to up to 2 years of treatment in clinical applications.
PTH mediated enhancement of closed fracture repair has been associated with a larger cartilaginous callus, 109 amplified chondrocyte recruitment, and maturation in early fracture callus, as well as an increase in canonical Wnt signaling. 110, 111 Intermittent PTH (10 mg/kg/day) enhanced closed fracture healing in rats by stimulating proliferation and differentiation of osteoprogenitor cells, increased production of bone matrix proteins, and enhanced osteoclastogenesis during callus remodeling. 112 In a closed fracture model in female cynomolgus monkeys PTH accelerated fracture healing by shrinking callus size and increasing the degree of mineralization of the fracture callus (accelerating callus remodeling). 94 However, when used in conjunction with devitalized allografts, PTH 1-34 (40 mg/kg/day) increased callus volume and mineral content, but did not affect allograft bone volume, osteoclasts, or resorption surfaces suggesting no increase in graft resorption. 103 PTH administration can also influence endothelial cells and stem cells which may aid in bone healing. 113 The impact PTH has on vascular regeneration as well as proliferation may aid in its anabolic capabilities for bone regeneration applications. Not only are bone endothelial cells capable of responding to PTH, 114 PTH enhances migration of CD45þ/ CD34þ (angiogenic progenitor cells) stem cells, 115 and increases the number of hematopoietic stem cells in the bone marrow that can be mobilized into the peripheral circulation. 116 Patients with primary hyperparathyroidism (PHPT) show an increased number of circulating CD45/CD34 stem cells in the peripheral blood. 117 Similarly, PTH levels in patients with untreated PHPT are correlated with elevated levels of circulating bone marrow-derived progenitor cells. 117 The ability of PTH to facilitate stem cell mobilization was corroborated by a phase 1 clinical trial where PTH enhanced CD34 cells in patients with inadequate CD34þ cell counts. 118 PTH also has been shown to increase proliferation of bone marrow stem cells and facilitate homing to sites of therapeutic need. 119, 120 In both athymic rats and pigs PTH significantly enhanced mesenchymal stem cell (MSC) migration to the lumbar region (location of cylindrical drill defects in two vertebral bodies) where they differentiated into bone forming cells. 108 There also is evidence for a synergistic effect of treatment with exogenous MSCs and PTH concomitantly when used to treat rib defects in athymic rats. 121 The impact PTH has on homing of cells to injury sites could be controlled outside of the already well-established pathways resulting in the anabolic effect of PTH. Though classic actions are generally accepted to occur through the aforementioned PKA and PKC signaling resulting from binding to PTHR1, there are other possibilities.
EFFECT OF LOCALLY DELIVERED PTH ON FRACTURE HEALING AND BONE DEFECT REGENERATION
Local delivery of PTH may allow for complete union in what would otherwise be non-union scenarios while reducing the costs and logistics associated with systemic delivery. The effect of locally delivered PTH on fracture healing and bone regeneration has not been as extensively investigated as systemically delivered PTH. However, there are some promising results. PTH delivered via polyethylene glycol (PEG) matrix resulted in a 1.9-fold increase in mineralized bone and 2.3-fold increase in the area of regeneration in bone chambers in rabbit calvaria. 122 Similarly, PEG matrices with PTH 1-34 (20 mg/ml) were used to fill a cylindrical defect around a titanium implant in the mandible between the first premolar and second molar in dogs. After 12 weeks, matrices infused with PTH had a significantly greater area fraction of newly formed bone within the defect compared to empty defects or defects filled with the PEG matrix alone. The PEG matrix with PTH was as effective as an autogeneous bone graft when comparing newly formed bone volume between groups.
123 PTH 1-34 linked to a fibrin hydrogel with a plasmin sensitive link has also been investigated as a method for enhanced bone healing. Cylindrical drill defects in the femur of sheep (8 mm diameter, 13 mm depth) were filled with the hydrogel containing PTH at 50, 100, 400, or 1000 mg/ ml. After 8 weeks the defects containing the hydrogel with 100 mg/ml exhibited an increased bone volume fraction as compared to the hydrogel control. 124 Similarly implantation of a gene-activated matrix containing a plasmid coding for PTH fragment 1-34 resulted in new bone filling a segmental defect in a rat.
125 PTH 1-34 covalently linked to a fibrin hydrogel (1 mg/ml) has also been shown to improve postoperative prognosis of subchondral bone cysts in the distal aspect of the proximal phalanx in horses. 126 Local delivery of PTH treatment has also been achieved through use of geneactivated matrices (GAM) which induce local production of PTH at the defect site. Treatment with PTH-GAM and a collagen matrix has been shown to promote bone regeneration in a craniomaxillofacial bone defect. 127 Though pulsatile release of PTH from biomaterial scaffolds has been explored, they have not been tested extensively in vivo for bone regeneration applications. 128, 129 One study showed PTH delivered via a cell free biomimetic nanofibrous scaffold designed to deliver a daily pulse of PTH for 21 days. This treatment resulted in improved regeneration of a critical-size calvarial defect with negligible systemic side effects in a mouse model. 130 These studies indicate that locally delivered PTH may prove to be effective and affordable substitutes for bone grafts for procedures such as the repair of critical size bone defects. Though studies indicate locally delivered PTH is a promising method for enhancing bone regeneration, much research is still needed to determine the delivery materials, PTH concentrations, and PTH delivery profiles that most efficaciously promote bone regeneration.
SUMMARY, CONCLUSION, AND FUTURE DIRECTIONS
Parathyroid hormone is an effective anabolic agent used in the treatment of osteoporosis. The evidence indicating beneficial effects of systemic administration of PTH on fracture healing are difficult to dispute. However, the timing and dose of PTH treatment have yet to be optimized. At least two studies have shown that PTH injections administered once to three times a week (as opposed to daily) may be sufficient to promote healing. 97, 106 However, the ideal window for PTH administration is unknown; 105 for example, is PTH treatment necessary during the entire healing process or could it be limited to healing phases that are most responsive to PTH? Though positive outcomes result from systemically administered PTH, can the same (or better) anabolic effect be achieved with locally delivered PTH for bone regeneration applications? Studies thus far indicate promising outcomes for locally delivered PTH for bone regeneration applications. However, it is unclear whether or not continuous or intermittent release is more efficacious. The findings that tonic PTH secretion plays a role in normal bone metabolism, 42 and post-menopausal women with mild primary hyperparathyroidism have a protective effect against osteoporosis 62 support the idea that low levels of continuously delivered PTH can be used to promote bone regeneration. Thus, future studies that more closely examine the efficacy of locally delivered PTH for bone regeneration applications could lead to improved treatments for segmental defects in bone.
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